CIITA promoter polymorphism impairs monocytes HLA-DR expression in patients with septic shock
Abstract
Monocyte HLA-DR is an increasingly recognized markers of sepsis-induced immunodepression, but its regulatory mechanisms remain poorly understood in sepsis. Several evidence for positive selection on the 5’ promoter region of HLA class II transactivator ( CIITA ) gene, the master regulator of MHC class II, have been gathered in the European population, and its role in sepsis has never been demonstrated, whilst suggested in autoimmune disease. We aim to describe the effect of rs3087456 polymorphism, localized on CIITA promoter III (pIII), on mortality of patients with septic shock, and investigate the mechanisms regulating HLA-DR expression. Genotyping of 203 patients with septic shock showed that, in A dominant model, GG genotype was associated with 28-day mortality (OR 2.29; 95%CI: 1.01 to 5.22; P = 0.043). Monocyte HLA-DR remained low in patients with GG genotype whereas it increases as early as at the end of the first week in intensive care in patients with AA or AG genotype. Using site-directed mutagenesis, in vitro reporter gene promoter activity of the pIII was decreased in GG genotype in monocyte cell line. Interferon-γ (IFN-γ) restored pIII activity in GG genotype as well as restore, in ex vivo experiment in healthy volunteers, CIITA pIII expression of GG genotype. Hereby, we demonstrated that rs3087456, a positively selected polymorphism of CIITA proximal promoter, significantly impact monocyte HLA-DR expression in patients with septic shock through CIITA promoter activity, that can be rescued using IFN-γ, offering a new perspective in genetic susceptibility to sepsis and targeted immunomodulatory therapy. Keypoints CIITA G-286A polymorphism reduces promotor activity and significantly impact monocyte HLA-DR expression and mortality in septic shock Downregulatory effects of CIITA G-286A polymorphism on monocyte HLA-DR expression can be reverse by IFN-γ in patients with septic shock
Related
- A germline KDM3C polymorphism impairs DNA repair and sensitizes to chemoradiotherapy
- Promoter hypomethylation associated with elevated TRIM33 expression in triple-negative breast cancer patients
- IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages
- An enhancer-like region regulates hrp3 promoter stage-specific gene expression in the human malaria parasite Plasmodium falciparum
- RNF152 promoter methylation and gene expression in oral premalignant lesions and oral squamous cell carcinoma: implications for epigenetic biomarker development
BibTeX
@article{miatello2026ciita,
title = {{CIITA promoter polymorphism impairs monocytes HLA-DR expression in patients with septic shock}},
author = {Jordi Miatello and Anne-Claire Lukaszewicz and Michael Carter and Valérie Faivre and Stéphane Hua and Kim Martinet and Christine Bourgeois and Lluis Quintana-Murci and Didier Payen and Michele Boniotto and Pierre Tissières},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2022.105291},
url = {https://hal.science/hal-05797241v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - CIITA promoter polymorphism impairs monocytes HLA-DR expression in patients with septic shock
AU - Jordi Miatello
AU - Anne-Claire Lukaszewicz
AU - Michael Carter
AU - Valérie Faivre
AU - Stéphane Hua
AU - Kim Martinet
AU - Christine Bourgeois
AU - Lluis Quintana-Murci
AU - Didier Payen
AU - Michele Boniotto
AU - Pierre Tissières
PY - 2026
DA - 2026/10/13
JO - iScience
DO - 10.1016/j.isci.2022.105291
UR - https://hal.science/hal-05797241v1
AB - Monocyte HLA-DR is an increasingly recognized markers of sepsis-induced immunodepression, but its regulatory mechanisms remain poorly understood in sepsis. Several evidence for positive selection on the 5’ promoter region of HLA class II transactivator ( CIITA ) gene, the master regulator of MHC class II, have been gathered in the European population, and its role in sepsis has never been demonstrated, whilst suggested in autoimmune disease. We aim to describe the effect of rs3087456 polymorphism, localized on CIITA promoter III (pIII), on mortality of patients with septic shock, and investigate the mechanisms regulating HLA-DR expression. Genotyping of 203 patients with septic shock showed that, in A dominant model, GG genotype was associated with 28-day mortality (OR 2.29; 95%CI: 1.01 to 5.22; P = 0.043). Monocyte HLA-DR remained low in patients with GG genotype whereas it increases as early as at the end of the first week in intensive care in patients with AA or AG genotype. Using site-directed mutagenesis, in vitro reporter gene promoter activity of the pIII was decreased in GG genotype in monocyte cell line. Interferon-γ (IFN-γ) restored pIII activity in GG genotype as well as restore, in ex vivo experiment in healthy volunteers, CIITA pIII expression of GG genotype. Hereby, we demonstrated that rs3087456, a positively selected polymorphism of CIITA proximal promoter, significantly impact monocyte HLA-DR expression in patients with septic shock through CIITA promoter activity, that can be rescued using IFN-γ, offering a new perspective in genetic susceptibility to sepsis and targeted immunomodulatory therapy. Keypoints CIITA G-286A polymorphism reduces promotor activity and significantly impact monocyte HLA-DR expression and mortality in septic shock Downregulatory effects of CIITA G-286A polymorphism on monocyte HLA-DR expression can be reverse by IFN-γ in patients with septic shock
SN - 2589-0042
ER -